Polymer nanoparticles coated by magnetic metal oxide and uses thereof
The invention provides nanoparticles consisting of a polymer which is a metal chelating agent coated with a magnetic metal oxide, wherein at least one active agent is covalently bound to the polymer, said nanoparticles may optionally further comprise at least one active agent physically or covalently bound to the outer surface of the magnetic metal oxide. Pharmaceutical compositions comprising these nanoparticles may be used, inter alia, for detection and treatment of tumors and inflammations.
1. A nanoparticle comprising: a metal chelating polymer core, and a magnetic metal oxide coating, said magnetic metal oxide coating coats said metal chelating polymer core, and TNF-related apoptosis-inducing ligand (Apo-2L), covalently bound to said metal chelating polymer core, wherein covalently includes binding via an amino group of said metal chelating polymer and an amino group of said TNF-related apoptosis-inducing ligand.
2. The nanoparticle of claim 1 , wherein said magnetic metal oxide is an iron oxide or a ferrite derived from an iron oxide.
3. The nanoparticle of claim 2 , wherein said iron oxide is magnetite, maghemite or a mixture thereof and said ferrite is an oxide of the formula (Fe,M)3O4, wherein M represents a transition metal ion.
4. The nanoparticle of claim 1 , further comprising at least one additional agent.
5. The nanoparticle of claim 1 , wherein said polymer is gelatin and said magnetic metal oxide is iron oxide.
6. The nanoparticle of claim 4 , wherein said at least one additional agent is cRGD peptide or peptidomimetic.
7. A method for inducing apoptosis, autophagy, or both in a cancer cell, comprising the step of contacting said cell with a nanoparticle of claim 1 .
8. The method of claim 7 , further comprising Gamma irradiating said cell.
9. The method of claim 7 , wherein said cancer cell is a glioma cell, a cancer stem cell, a carcinoma cell, a breast cancer cell, or a lung cancer cell.
10. The method of claim 7 , wherein said inducing apoptosis, autophagy, or both in a cancer cell is treating a patient afflicted with cancer.
11. The method of claim 10 , wherein said patient is afflicted with glioma, carcinoma, breast cancer or a lung cancer.
12. The method of claim 7 , further contacting said cell with a proteasome inhibitor.
13. The method of claim 7 , wherein said nanoparticle is non-toxic to a non-cancer cell.
14. A method for treating a subject afflicted with glioma, comprising the step of administering to said subject an effective amount of a composition comprising said nanoparticle of claim 1 .
15. The method of claim 14 , further comprising the step of administering to said subject a proteasome inhibitor.
16. The method of claim 14 , wherein said nanoparticle is non-toxic to a non-cancer cell.
17. The method of claim 14 , further comprising Gamma irradiating said glioma.
18. The nanoparticle of claim 1 , wherein said nanoparticle is non-toxic to a non-cancer cell.
19. The nanoparticle of claim 1 , further comprising a drug, a dye label, a contrast agent, or combination thereof.
20. The nanoparticle of claim 19 , wherein said dye label is a fluorescent dye.
21. A composition comprising the nanoparticle of claim 1 and a pharmaceutical acceptable carrier.
22. A method for preparing a nanoparticle according to claim 1 , comprising the following consecutive steps:
a. mixing an aqueous solution comprising a soluble metal chelating polymer with at least one soluble metal salt;
b. oxidizing metal ions formed in said solution;
c. forming said nanoparticle in said solution by adjusting acidity of said solution to a basic pH;
d. adding an additional portion of a metal salt to said solution;
e. oxidizing metal ions formed in said solution;
f. adjusting acidity of said solution to a basic pH;
g. repeating steps (d) to (f) at least once;
h. functionalizing said nanoparticle;
i. contacting said functionalized nanoparticle with at least Apo-2L; and j. blocking remaining active sites on a surface of said nanoparticle.
23. The method according to claim 22 , wherein said polymeric metal chelating agent comprises functional groups, wherein said functional groups comprise amino, hydroxyl, carboxylate, —SH, ether, immine, phosphate, and sulfide groups.
24. The method according to claim 22 , wherein said polymeric metal chelating agent is gelatin, polymethylenimine, dextran, chitosan, polylysine, polyvinylpyrrolidone, or combination thereof.
25. The method according to claim 22 , wherein said functionalizing said nanoparticle comprises contacting said nanoparticle with acryloyl chloride, divinyl sulfone (DVS), dicarbonyl immidazole, ethylene glycolbis(sulfosuccinimidylsuccinate), m-maleimidobenzoic acid N-hydroxysulfosuccinimide ester, or any combination thereof.
26. The method according to claim 22 , wherein said functionalizing further comprises coating said nanoparticle with a coating polymer.
27. The method according to claim 26 , wherein said functionalizing further comprises crosslinking said coating polymer with acryloyl chloride, divinyl sulfone (DVS), dicarbonyl immidazole, ethylene glycolbis(sulfosuccinimidylsuccinate), m-maleimidobenzoic acid N-hydroxysulfosuccinimide ester, or any combination thereof.
28. The method according to claim 22 , wherein said aqueous solution comprises: a drug, a dye label, a contrast agent, or any combination thereof.
29. The method according to claim 22 , wherein said soluble metal chelating polymer is bound to said Apo-2L.
30. The method according to claim 28 , wherein said dye label is a fluorescent dye.
31. The method according to claim 29 , wherein said magnetic metal oxide is bound to said Apo-2L.